Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV

Repurposing FDA-approved drugs that treat respiratory infections caused by coronaviruses, such as SARS-CoV-2 and MERS-CoV, could quickly provide much needed antiviral therapies. In the current study, the potency and cellular toxicity of four fluoroquinolones (enoxacin, ciprofloxacin, levofloxacin, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Scroggs, Stacey L. P., Offerdahl, Danielle K., Flather, Dylan P., Morris, Ciera N., Kendall, Benjamin L., Broeckel, Rebecca M., Beare, Paul A., Bloom, Marshall E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822115/
https://www.ncbi.nlm.nih.gov/pubmed/33374514
http://dx.doi.org/10.3390/v13010008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822115/
https://www.ncbi.nlm.nih.gov/pubmed/33374514
http://dx.doi.org/10.3390/v13010008

Ejemplares similares